iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation

This phase I trial studies the best dose and side effects of mesenchymal stromal cells-derived exosomes with KrasG12D siRNA (iExosomes) in treating participants with pancreatic cancer with KrasG12D mutation that has spread to other places in the body. iExosomes may work better at treating pancreatic cancer.

Trial Details

NCT ID

NCT03608631

Phase

PHASE1 / PHASE2

Sponsor

M.D. Anderson Cancer Center

Status

RECRUITING

Cancer Type

Pancreatic Ductal Adenocarcinoma Pancreatic Cancer

Interventions

Mesenchymal Stromal Cells-derived Exosomes with KRAS G12D siRNA

Locations (sample)

Houston, Texas, United States|29.76328,-95.36327

Key Eligibility Criteria

Patients with histologically confirmed metastatic pancreatic ductal adenocarcinoma harboring KrasG12D mutation
Patients must have documented progression or stable disease on one or more lines of systemic therapy. If stable disease, patient must have complete…
KrasG12D mutation status will be informed from any previous routine molecular profiling (using commercial assays such as Foundation One, Caris, Onc…
ECOG (Eastern Cooperative Oncology Group) performance status of 0-1

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Ductal Adenocarcinoma Pancreatic Cancer Trials on Trialify →